JPH03232898A - Functional polypeptide - Google Patents
Functional polypeptideInfo
- Publication number
- JPH03232898A JPH03232898A JP2024469A JP2446990A JPH03232898A JP H03232898 A JPH03232898 A JP H03232898A JP 2024469 A JP2024469 A JP 2024469A JP 2446990 A JP2446990 A JP 2446990A JP H03232898 A JPH03232898 A JP H03232898A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- egf
- cell adhesion
- activity
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 50
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 46
- 230000021164 cell adhesion Effects 0.000 claims abstract description 33
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 16
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 8
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims abstract description 6
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims abstract description 5
- 229940116978 human epidermal growth factor Drugs 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 28
- 239000013612 plasmid Substances 0.000 abstract description 25
- 241000588724 Escherichia coli Species 0.000 abstract description 11
- 230000010261 cell growth Effects 0.000 abstract description 4
- JHKXZYLNVJRAAJ-UHFFFAOYSA-N methionyl-alanine Chemical group CSCCC(N)C(=O)NC(C)C(O)=O JHKXZYLNVJRAAJ-UHFFFAOYSA-N 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 230000001133 acceleration Effects 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 35
- 239000012634 fragment Substances 0.000 description 20
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000036978 cell physiology Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- LRPZJPMQGKGHSG-XGEHTFHBSA-N Arg-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)O LRPZJPMQGKGHSG-XGEHTFHBSA-N 0.000 description 1
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 1
- RVHGJNGNKGDCPX-KKUMJFAQSA-N Asn-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N RVHGJNGNKGDCPX-KKUMJFAQSA-N 0.000 description 1
- VWADICJNCPFKJS-ZLUOBGJFSA-N Asn-Ser-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O VWADICJNCPFKJS-ZLUOBGJFSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 1
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CYHMMWIOEUVHHZ-IHRRRGAJSA-N Cys-Met-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CYHMMWIOEUVHHZ-IHRRRGAJSA-N 0.000 description 1
- -1 DEAE ion Chemical class 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150084418 EGF gene Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- CELXWPDNIGWCJN-WDCWCFNPSA-N Gln-Lys-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CELXWPDNIGWCJN-WDCWCFNPSA-N 0.000 description 1
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- ITVBKCZZLJUUHI-HTUGSXCWSA-N Glu-Phe-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ITVBKCZZLJUUHI-HTUGSXCWSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- HPAIKDPJURGQLN-KBPBESRZSA-N Gly-His-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 HPAIKDPJURGQLN-KBPBESRZSA-N 0.000 description 1
- WRFOZIJRODPLIA-QWRGUYRKSA-N Gly-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O WRFOZIJRODPLIA-QWRGUYRKSA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KSZCCRIGNVSHFH-UWVGGRQHSA-N Leu-Arg-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O KSZCCRIGNVSHFH-UWVGGRQHSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- MDXAULHWGWETHF-SRVKXCTJSA-N Met-Arg-Val Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CCCNC(N)=N MDXAULHWGWETHF-SRVKXCTJSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 1
- QUBVFEANYYWBTM-VEVYYDQMSA-N Pro-Thr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUBVFEANYYWBTM-VEVYYDQMSA-N 0.000 description 1
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- GYXVUTAOICLGKJ-ACZMJKKPSA-N Ser-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N GYXVUTAOICLGKJ-ACZMJKKPSA-N 0.000 description 1
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- IRKWVRSEQFTGGV-VEVYYDQMSA-N Thr-Asn-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IRKWVRSEQFTGGV-VEVYYDQMSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- VYVBSMCZNHOZGD-RCWTZXSCSA-N Thr-Val-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VYVBSMCZNHOZGD-RCWTZXSCSA-N 0.000 description 1
- PEYSVKMXSLPQRU-FJHTZYQYSA-N Trp-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O PEYSVKMXSLPQRU-FJHTZYQYSA-N 0.000 description 1
- OFCKFBGRYHOKFP-IHPCNDPISA-N Trp-Asp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N OFCKFBGRYHOKFP-IHPCNDPISA-N 0.000 description 1
- QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 description 1
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 1
- MPKPIWFFDWVJGC-IRIUXVKKSA-N Tyr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O MPKPIWFFDWVJGC-IRIUXVKKSA-N 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- PQPWEALFTLKSEB-DZKIICNBSA-N Tyr-Val-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PQPWEALFTLKSEB-DZKIICNBSA-N 0.000 description 1
- WKWJJQZZZBBWKV-JYJNAYRXSA-N Val-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WKWJJQZZZBBWKV-JYJNAYRXSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 1
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- CEKSLIVSNNGOKH-KZVJFYERSA-N Val-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C(C)C)N)O CEKSLIVSNNGOKH-KZVJFYERSA-N 0.000 description 1
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、新規ポリペプチドに関し、更に詳しくはヒト
フィブロネクチンの細胞接着ドメインポリペプチドと、
ヒト上皮成長因子とが共有結合した新規な機能性ポリペ
プチドに関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a novel polypeptide, and more particularly to a cell adhesion domain polypeptide of human fibronectin;
This invention relates to a novel functional polypeptide covalently bound to human epidermal growth factor.
フィブロネクチン(以下、FNと表示する)は血漿や細
胞外マトリックスに存在する糖タンパク質で、多彩な機
能を持つことが知られている〔アニュアル レビュー
オブ バイオケミス ト リ − (八nnual
Review of Biochemistry
) 、第57巻、第375〜413頁(1988))。Fibronectin (hereinafter referred to as FN) is a glycoprotein present in plasma and extracellular matrix, and is known to have a variety of functions [Annual Review
Of Biochemistry - (8annual
Review of Biochemistry
), Vol. 57, pp. 375-413 (1988)).
天然のFNを創傷治癒、点眼薬等の医薬品や化粧品に利
用する試みがなされているが、血液から採取するために
供給に制限があること、コスト高であること、また、病
原性の細菌やウィルス等による汚染の可能性があるなど
の理由により、実用化されていない。また、天然のFN
の機能ドメインを取出して利用することも同様の理由か
ら実用化されていない。Attempts have been made to use natural FN for wound healing, medicines such as eye drops, and cosmetics, but there are limited supplies because it is collected from blood, high costs, and the risk of pathogenic bacteria and cosmetics. It has not been put into practical use due to the possibility of contamination by viruses, etc. Also, natural FN
For the same reason, extracting and using the functional domain of the system has not been put to practical use.
そこで本発明者らは、ヒ)FNの細胞接着ドメインをコ
ードするcDNA断片を発現ベクターに接続して大腸菌
に導入することにより、細胞接着活性ポリペプチド及び
その製造方法を開発し、特許出願した(特開平1−20
6998号)。Therefore, the present inventors developed a cell adhesion active polypeptide and its production method by connecting a cDNA fragment encoding the cell adhesion domain of human FN to an expression vector and introducing it into E. coli, and filed a patent application ( Japanese Patent Publication No. 1-20
No. 6998).
一方、上皮成長因子(以下EGFと表示する)は、上皮
細胞をはじめとする種々の細胞の増殖と分化の促進、オ
ルニチン脱炭酸酵素活性の元通とプトレッシンの蓄積、
胃酸分泌抑制、核酸、タンパク合成の促進、低分子物質
の細胞内輸送の促進、解糖の促進、ホルモン分泌・合成
の促進などの多彩な生物作用を示すポリペプチドであり
〔アニュアル レビュー オブ バイオケミ ス ト
リ − (Annual Review of
Biochemistry)第48巻、第193〜21
6頁(1979))、その細胞増殖促進活性から、創傷
治癒、潰瘍治癒等の効果が認められている。On the other hand, epidermal growth factor (hereinafter referred to as EGF) promotes the proliferation and differentiation of various cells including epithelial cells, restores ornithine decarboxylase activity, and accumulates putrescine.
It is a polypeptide that exhibits a variety of biological effects such as suppressing gastric acid secretion, promoting nucleic acid and protein synthesis, promoting intracellular transport of low-molecular-weight substances, promoting glycolysis, and promoting hormone secretion and synthesis [Annual Review of Biochemistry] to
Annual Review of
Biochemistry) Volume 48, Nos. 193-21
6 (1979)), and its cell proliferation-promoting activity has been recognized to have effects on wound healing, ulcer healing, etc.
前記したごとく、EGFにはその細胞増殖促進作用から
創傷治癒効果が認められているが、これに細胞接着活性
を合せ持たせられれば、°細胞への親和性を高めること
ができ、局所への到達(ドラッグデリバリ−)システム
や、徐放性薬剤の開発等、EGFの利用上非常に有効で
ある。As mentioned above, EGF has been shown to have a wound healing effect due to its cell proliferation-promoting effect, but if it can also have cell adhesion activity, it would be possible to increase its affinity for cells and provide local therapy. This is very effective for the use of EGF, such as in the development of drug delivery systems and sustained release drugs.
すなわち本発明の目的は、細胞接着活性と、細胞増殖促
進活性とを同時に兼ね備えた新規なポリペプチドを開発
し、更にその製造方法を提供することにある。That is, an object of the present invention is to develop a novel polypeptide that simultaneously has cell adhesion activity and cell proliferation promoting activity, and to provide a method for producing the same.
本発明を概説すれば、本発明は機能性ポリペプチドであ
って、細胞接着活性と、細胞増殖促進活性とを合せ持つ
新規なポリペプチドに関する。To summarize the present invention, the present invention relates to a novel polypeptide that is a functional polypeptide and has both cell adhesion activity and cell proliferation promoting activity.
本発明者らは、FNの細胞接着活性と、EGFの細胞増
殖促進活性を兼ね備えた新規ポリペプチドの構築、及び
その製造方法について研究し、ヒトFNの細胞接着ドメ
インと、ヒトEGFが直接又はリンカ−ペプチドを介し
て結合した新規な機能性ポリペプチドを遺伝子工学的に
作製した。The present inventors researched the construction of a novel polypeptide that has both the cell adhesion activity of FN and the cell proliferation promoting activity of EGF, and a method for producing the same. - Genetically engineered a novel functional polypeptide linked via a peptide.
この新規な機能性ポリペプチドの生物活性を調べた結果
、細胞接着活性と、細胞増殖促進活性の両方の活性を有
することを見出した。As a result of examining the biological activities of this novel functional polypeptide, it was found that it has both cell adhesion activity and cell growth promoting activity.
以下、本発明を具体的に説明する。The present invention will be explained in detail below.
ヒ)FNのタンパク質の一次構造については、ジ エン
ボ ジャーナル(The EMBOJournal)、
第4巻、第1755〜1759頁(1985)に記載さ
れている。まtこ、その細胞接着ドメインをコードする
cDNAクローン(pLF5)についてはバイオケミス
トリー(Biochemistry)第25巻、第49
36〜4941頁(1986)に記載されている。本発
明者らは、pLF5から、細胞接着ドメインに対するc
DNA断片を取出し、これを発現ベクターに接続して
大腸菌に導入することにより、細胞接着活性ポリペプチ
ド及びその製造方法を開発し特許出願しjこ(特開平↑
−206998号)。本発明で必要とされる細胞接着ド
メインのcDNAは、特開平1−206998号公報に
記載されている組換え体プラスミドpTF7021を用
いることができる。pTF7021はFNのpro+2
39−Met1517(279アミノ酸残基)を発現す
るプラスミドである。pTF7021の翻訳領域のC末
端の終止コドンの直前にクローニングサイト、例えばN
coIサイトを導入することにより、細胞接着ドメイン
のcDNAと他のポリペプチドをコードするDNAを連
結させることができる。h) For the primary structure of the FN protein, see The EMBOJournal,
4, pp. 1755-1759 (1985). Regarding the cDNA clone (pLF5) encoding the cell adhesion domain, see Biochemistry Vol. 25, No. 49.
36-4941 (1986). From pLF5, we found that c
By extracting a DNA fragment, connecting it to an expression vector, and introducing it into Escherichia coli, we developed a cell adhesion active polypeptide and a method for its production, and filed a patent application (Unexamined Japanese Patent Publication No.
-206998). As the cDNA of the cell adhesion domain required in the present invention, recombinant plasmid pTF7021 described in JP-A-1-206998 can be used. pTF7021 is FN pro+2
This is a plasmid expressing 39-Met1517 (279 amino acid residues). A cloning site, e.g. N
By introducing a coI site, the cDNA of the cell adhesion domain and the DNA encoding another polypeptide can be linked.
本発明による新規な機能性ポリペプチドは、下記一般式
I:
C2,、−(X)、、−BGF ・・−CI 〕〔
式中、C277はヒトフィブロネクチンの細胞接着ドメ
インのpr01239−Serl!i+5に相当する2
77アミノ酸ポリペプチド残基を示し、下記式■:
Pro Asp Thr
Pro Pro 5er
Val Arg Tyr
Asp Val Ala
八sp 八sn 八1a
Pro Gay Thr
Ser Val Tyr
Leu Arg Gly
Met Arg Val
11e Asp Leu
Ser Pro Val
Glu Leu 5er
Val Val Leu
Glu Tyr Val
Glu Gln His
八rg Gln Lys
Thr Trp Ala
Thr Asn Phe
Lys Asn Glu
11e Ser Pr。The novel functional polypeptide according to the present invention has the following general formula I: C2,, -(X),, -BGF...-CI] [
In the formula, C277 is pr01239-Serl! of the cell adhesion domain of human fibronectin. 2 corresponding to i+5
The 77 amino acid polypeptide residues are represented by the following formula ■: Pro Asp Thr Pro Pro 5er Val Arg Tyr Asp Val Ala 8sp 8sn 81a Pro Gay Thr Ser Val Tyr Leu Arg Gly Met Arg Val 11e Asp Leu Ser Pro Val Glu Leu 5er Val Val Leu Glu Tyr Val Glu Gln His 8rg Gln Lys Thr Trp Ala Thr Asn Phe Lys Asn Glu 11e Ser Pr.
Thr 八sn Leu Val Ser Val Gill −Ser Thr Thr Gly Leu Pr。Thr 8 sn Leu Val Ser Val Gill-Ser Thr Thr Gly Leu Pr.
Leu Glu Ser Leu Ser Pr。Leu Glu Ser Leu Ser Pr.
Asp Ser Thr 八1a IIe Arg 八rg Pr。Asp Ser Thr 81a IIe Arg 8rg Pr.
八1a し8u Val Thr Ala 1e Pr。81a Shi8u Val Thr Ala 1e Pr.
しys Pr。Yes Pr.
Ala Ser Thr Pr。Ala Ser Thr Pr.
1a Pr。1a Pr.
Arg Pr。Arg Pr.
八sn 1y しeu 1e Pr。Eight sns 1y Seu 1e Pr.
Pr。Pr.
Pr。Pr.
Thr Val Ser Gay Val Ser Glu Thr Asn Arg 旧S Arg Ser Thr Asn 1y Arg Thr Ala Tyr Gln Thr Val Thr しys IIe 1y Ser 八1a flis Glu 1e Glu 1y Gin Asp Ser Val Gay Glu 八1a Asp 1y Pr。Thr Val Ser Gay Val Ser Glu Thr Asn Arg Old S Arg Ser Thr Asn 1y Arg Thr Ala Tyr Gln Thr Val Thr Yes IIe 1y Ser 81a flis Glu 1e Glu 1y Gin Asp Ser Val Gay Glu 81a Asp 1y Pr.
Asp 1e Phe Thr Pr。Asp 1e Phe Thr Pr.
Asp Thr Tyr Arg Gin Leu Leu Thr Glu Phe Thr Tyr Arg IIe Lys Asp Thr IIe Glu Arg Leu Val Glu Ser Glu Leu Val Thr Thr 1e Thr Gay Ser Pr。Asp Thr Tyr Arg Gin Leu Leu Thr Glu Phe Thr Tyr Arg IIe Lys Asp Thr IIe Glu Arg Leu Val Glu Ser Glu Leu Val Thr Thr 1e Thr Gay Ser Pr.
Phe 5er Val His Thr Gly His Phe Val Pr。Phe 5er Val His Thr Gly His Phe Val Pr.
Thr 八5n Val 5er Glu 5er Thr Val Val Val 11e Ser 八rg Tyr Gly Gly Val Pr。Thr 85n Val 5er Glu 5er Thr Val Val Val 11e Ser 8rg Tyr Gly Gly Val Pr.
Ser Gly
11e Thr
八sp 5er
11e 八sn
Ser
八sp IIe
Trp l1e
Tyr Arg
Ser Gay
flis 5er
Leu Thr
Ice Val
Pro Leu
Ser 八5p
Ala 八1a
Trp Asp
Tyr Arg
Asn 5er
Gay 5er
Leu 1ys
Val Tyr
Pro Ala
Tyr 八rg
[’llI]
で表される配列を有し、Xはメチオニル−アラニン残基
(Met−Ala)を示し、nは1又は零の数を示し、
EGFはヒト上皮成長因子のアミノ酸残基を示し、下記
式■:
Asn Ser Asp Ser Glu Cys P
ro Leu Ser tlis八spへ Gly
Tyr Cys Leu )lis Asp
Gly Val CysMet Tyr Ile
Glu Ala Leu Asp Lys Tyr
AlaCys 八sn Cys Vat Va
l Gly Tyr Ile Gly Gl
u八rへ Cys Gin Tyr 八rg
Asp Leu Lys Trp TrpG
lu Leu Arg ・・・[:III
]で表される配列を有する〕で表されることを特徴とす
る機能性ポリペプチドである。Ser Gly 11e Thr 8sp 5er 11e 8sn Ser 8sp IIe Trp l1e Tyr Arg Ser Gay flis 5er Leu Thr Ice Val Pro Leu Ser 85p Ala 81a Trp Asp Tyr Arg Asn 5er Gay 5er Leu 1ys Val Tyr Pro Ala Tyr 八rg['llI], X represents a methionyl-alanine residue (Met-Ala), n represents the number of 1 or zero,
EGF represents the amino acid residue of human epidermal growth factor, and has the following formula: Asn Ser Asp Ser Glu Cys P
ro Leu Ser tlis to 8sp Gly
Tyr Cys Leu )lis Asp
Gly Val CysMet Tyr Ile
Glu Ala Leu Asp Lys Tyr
AlaCys 8sn Cys Vat Va
l Gly Tyr Ile Gly Gl
To u8r Cys Gin Tyr 8rg
Asp Leu Lys Trp TrpG
lu Leu Arg...[:III
] It is a functional polypeptide characterized by having a sequence represented by ].
なお、本明細書において、アミノ酸に付された頁数字は
、EMB L データバンク(BMBLDATA B
へNK)中のFNのcDNA配列を翻訳して得られるア
ミノ酸配列に付されたN末からのアミノ酸残基数を示す
。In addition, in this specification, the page numbers assigned to amino acids are from the EMB L Data Bank (BMBLDATA B
The number of amino acid residues from the N-terminus added to the amino acid sequence obtained by translating the cDNA sequence of FN in NK) is shown.
ヒ)EGFについては、そのアミノ酸配列が明らかとな
っており〔ネーチャー(Nature)、第257巻、
第325〜327頁(1975) :]0
そのアミノ酸残基数は53である。このヒトEGFをコ
ードするDNAについては、そのアミノ酸配列に基づい
て設計したDNAを化学合成するこ舌により得るこ七が
できる。この化学合成によって得られたヒ) EGFを
コードするDNAを、前記pTF7021から誘導され
たプラスミドpTF7520の翻訳領域の3′末端Nc
oIサイ1−に接続することにより、FNの細胞接着ド
メインとヒトEGFとが連結したポリペプチドを発現す
る組換え体プラスミドが得られる(第1図及び第2図参
照)。h) Regarding EGF, its amino acid sequence has been clarified [Nature, Vol. 257,
Pages 325-327 (1975):]0 The number of amino acid residues is 53. The DNA encoding human EGF can be obtained by chemically synthesizing DNA designed based on its amino acid sequence. The human EGF-encoding DNA obtained by this chemical synthesis was inserted into the 3'-terminus Nc of the translated region of plasmid pTF7520 derived from pTF7021.
By connecting to oIcy1-, a recombinant plasmid expressing a polypeptide in which the cell adhesion domain of FN and human EGF are linked can be obtained (see FIGS. 1 and 2).
前記プラスミドにおける連結部には、Nc。At the junction in the plasmid, there is Nc.
Iザイトに由来するメチオニルアラニン残基(前記1式
においてXと表記)がリンカ−として含まれる。リンカ
−の有無は、本発明の効果を左右するものではないが、
必要とあれば部位特異的変異の手法により、容易に除去
することができる。A methionylalanine residue (denoted as X in the above formula 1) derived from Izyte is included as a linker. Although the presence or absence of a linker does not affect the effects of the present invention,
If necessary, it can be easily removed by site-directed mutagenesis.
得られたプラスミドを大腸菌に導入し、適当な条件下に
培養することにより、目的ポリペプ1
チドが大腸菌内に蓄積される。発現の確認にはイムノブ
ロッティングが用いられる。組換え大腸菌の全菌体タン
パク質を5DS−ポリアクリルアミド電気泳動で分離し
た後、泳動パターンをニトロセルロース膜に移し取る。By introducing the obtained plasmid into E. coli and culturing it under appropriate conditions, the target polypeptide is accumulated in E. coli. Immunoblotting is used to confirm expression. After the total cell proteins of the recombinant E. coli are separated by 5DS-polyacrylamide electrophoresis, the migration pattern is transferred to a nitrocellulose membrane.
FNの細胞接着ドメインを認識するモノクローナル抗体
(FN12−8、宝酒造)及びヒトEGFを認識するモ
ノクローナル抗体(湧永製薬)で検出されるバンドが目
的のポリペプチドである。The target polypeptide is the band detected with a monoclonal antibody that recognizes the cell adhesion domain of FN (FN12-8, Takara Shuzo) and a monoclonal antibody that recognizes human EGF (Yunaga Pharmaceutical).
目的ポリペプチドは、大腸菌菌体内で不溶化し、いわゆ
る封入体を形成する。このため、目的ポリペプチドの精
製は、例えば次のように行う。The target polypeptide is insolubilized within the E. coli cells to form so-called inclusion bodies. Therefore, the target polypeptide is purified, for example, as follows.
組換え大腸菌をL−ブロスなどの培地に培養し、集菌し
た後、超音波処理により菌体破砕液を得、これを遠心分
離して目的ポリペプチドを含む封入体の沈殿を得る。こ
の沈殿を種々の界面活性剤〔例えばトリ1−ン(Tri
ton) X −100等]を含む緩衝液に懸濁、遠心
分離を繰返すことにより、沈殿を洗浄する。この沈殿を
尿素及2
びジチオスレイトールを含む緩衝液に溶解する。After culturing the recombinant E. coli in a medium such as L-broth and collecting the bacteria, a bacterial cell disruption solution is obtained by ultrasonication, and this is centrifuged to obtain a precipitate of inclusion bodies containing the target polypeptide. This precipitate was treated with various surfactants [e.g.
The precipitate is washed by repeating suspension in a buffer containing 100 ton) X-100, etc. and centrifugation. This precipitate is dissolved in a buffer containing urea and dithiothreitol.
次いでこの可溶化液をDEAEイオン交換体のカラムク
ロマトグラフィーにより精製した後、透析法等による方
法でリフォールディングを行う。以上の操作により、目
的のポリペプチドを精製することができる。Next, this solubilized solution is purified by DEAE ion exchanger column chromatography, and then refolded by a method such as dialysis. By the above operations, the polypeptide of interest can be purified.
得られたポリペプチドは、BHKやNHK細胞に対する
細胞接着活性の測定に用いられる。The obtained polypeptide is used to measure cell adhesion activity against BHK and NHK cells.
細胞接着活性の測定は、例えばルオスラティ (Ruo
slahti)等の方法(メソッズ イン エンザイモ
ロジー(MethodSin Bnzymology)
、第82巻、第803〜831頁(1981)]に準じ
て行う。すなわち、試料をコートした後、BSAでブロ
ッキングしたマイクロタイタープレートに、BHK又は
NRK細胞の懸濁液を添加し、37℃で約1時間インキ
ュベートした後、未吸着の細胞を洗浄した後、ホルマリ
ン固定し、伸展した細胞の割合を顕微鏡下に測定するこ
とにより、細胞接着の強さを測定することができる。Measurement of cell adhesion activity can be performed, for example, using Ruo
slahti) etc. (Methods in Enzymology)
, Vol. 82, pp. 803-831 (1981)]. That is, after coating the sample, a suspension of BHK or NRK cells was added to a microtiter plate blocked with BSA, incubated at 37°C for about 1 hour, and unadsorbed cells were washed, followed by formalin fixation. However, the strength of cell adhesion can be measured by measuring the proportion of cells that have spread under a microscope.
一方、EGF活性は、細胞増殖促進の指標と3
なる311−チミジンの取込み活性を測定することによ
り測定可能であり、例えば、カーペンタ−(Carpe
nter)等の方法〔ジャーナル オブ セル フィジ
オロジ−(Journal of Ce1l Phys
iology)、第88巻、第227〜237頁(19
76)〕に準じて測定することができる。On the other hand, EGF activity can be measured by measuring the uptake activity of 311-thymidine, which is an indicator of cell proliferation promotion.
[Journal of Cell Physiology (Journal of Cell Physiology)
iology), Vol. 88, pp. 227-237 (19
76)].
すなわぢ、試料を添加した培地中でNRK細胞を18時
間培養した後、3H−チミジンを加え、更に6時間培養
する。細胞をガラスフィルターに吸着させ、液体シンチ
レーションカウンターにより細胞に取込まれた3H−チ
ミジン測定し、EGFとしての細胞増殖活性を測定する
ことができる。That is, after culturing NRK cells in a medium supplemented with the sample for 18 hours, 3H-thymidine is added and the cells are further cultured for 6 hours. Cells are adsorbed onto a glass filter, 3H-thymidine incorporated into the cells is measured using a liquid scintillation counter, and cell proliferation activity as EGF can be measured.
以下、本発明を実施例により具体的に説明するが、本発
明はこれら実施例に限定されない。EXAMPLES Hereinafter, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to these Examples.
実施例1.FNの細胞接着ドメインと、ヒ)EGFが結
合したポリペプチドをコー
ドするプラスミドの構築
(1−1)細胞接着ドメインpr01239−Ser1
5154
(277アミノ酸残基)をコードす
るプラスミドの構築
特開平1−206998号公報に記載されている組換え
体プラスミドpTF7021の翻訳領域の終止コドンの
直前に部位特異的変異の手法により、NcoIサイトを
導入したプラスミドを構築した。pTF7021へのN
c ofサイトの導入は、オリゴヌクレオチドd [p
CTATTACACCATGGATGGTTTGコを合
成し、サイト−ダイレクチイド ミュークジェネシス
システム ミュータン−K (Site−direct
ed mutagenesis system Mut
an−K) [全酒造]を用いて行った。このNcoI
サイトの導入に伴い細胞接着ドメインのC末端のG1n
15+61etlS+’7はMetI516−va11
517に置き変わっている。得られたプラスミドをpT
F7520と命名した。Example 1. Construction of a plasmid encoding a polypeptide bound to the cell adhesion domain of FN and human EGF (1-1) Cell adhesion domain pr01239-Ser1
Construction of a plasmid encoding 5154 (277 amino acid residues) An NcoI site was created by site-directed mutagenesis just before the stop codon in the translation region of the recombinant plasmid pTF7021 described in JP-A-1-206998. The introduced plasmid was constructed. N to pTF7021
The introduction of the c of site is performed using the oligonucleotide d[p
Synthesize CTATTACACCATGGATGGTTTG and generate cyto-directed mucgenesis.
System Mutan-K (Site-direct
ed mutagenesis system Mut
an-K) [Zen Shuzo]. This NcoI
G1n at the C-terminus of the cell adhesion domain due to the introduction of the site
15+61etlS+'7 is MetI516-va11
It has been replaced by 517. The obtained plasmid is pT
It was named F7520.
(1−2)ヒトEGFをコードする合成りNAの調製
ヒトEGFをコードするDNAの塩基配列は、そのアミ
ノ酸配列に基づいて設計した。EGF5
のN東側、C末側2つの部分に分け、N東側センス鎮、
EGF−1,84mar、N東側アンチセンス釦、EG
F−2,36mar、C東側センス鎖、EGF−3,8
8mar、C東側アンチセンス鎖、EGF−4,86m
er、(配列は第1図参照)の4本のDNAをアプライ
ド バイオシステムズ社のDNA合成機を用いて合成し
た。(1-2) Preparation of synthetic NA encoding human EGF The base sequence of DNA encoding human EGF was designed based on its amino acid sequence. EGF5 is divided into two parts, N east side and C terminal side, N east side Sensu town,
EGF-1, 84mar, N east side antisense button, EG
F-2,36mar, C east sense strand, EGF-3,8
8mar, C east antisense strand, EGF-4, 86m
er, (see Figure 1 for the sequence) were synthesized using an Applied Biosystems DNA synthesizer.
EGF−2、EGF−3についてはT4ポリヌクレオチ
ドキナーゼ(T4 PNK)を用いて5′末端をリン
酸化した後、アニーリング操作により二重鎖とした。す
なわち、1.5μgのEGF−2,1,5μgのEGF
−3をそれぞれT4 PNK用バッファー[50mM
トリス(Tris)HCI 、pH7,6,10mM
MgCl□、10mMDTT]、1 mMA T P及
び5ユニツトのT4 PNKを含む18μlの溶液中
で37℃、1時間インキュベートし、65℃、10分の
処理で反応を停止した。リン酸化の後、EGF−1とE
GF−2、EGF−3とEGF−4をそれぞれ等景況ぜ
て70℃に20分間保持した後、徐々に室温に戻6
した。EGF-2 and EGF-3 were phosphorylated at their 5' ends using T4 polynucleotide kinase (T4 PNK), and then made into double strands by annealing. That is, 1.5 μg of EGF-2, 1.5 μg of EGF
-3 and T4 PNK buffer [50mM
Tris HCI, pH 7, 6, 10mM
MgCl□, 10 mM DTT], 1 mM TP, and 5 units of T4 PNK were incubated at 37°C for 1 hour, and the reaction was stopped by treatment at 65°C for 10 minutes. After phosphorylation, EGF-1 and E
GF-2, EGF-3, and EGF-4 were each kept at 70° C. for 20 minutes, and then gradually returned to room temperature.
得られた二重鎖DNAのうちEGF−1十EGF−2の
2.0μg 、EGF−3+EGF−4の2.0μgを
ライゲーション反応液(66mMト リ ス HCI
、 p)17.6 、6.6 mM MgC1
,、0,5mMATP、10mM DTT) 、45
Qユニ7トのT4 DNAIJガーゼを含む80μ
lの溶液中で16℃、30分間インキュベートした。6
5℃、10分の処理で反応を停止した後、アガロースゲ
ル電気泳動を行い、目的の1?2bpのDNA断片を回
収した。Of the double-stranded DNA obtained, 2.0 μg of EGF-1 + EGF-2 and 2.0 μg of EGF-3 + EGF-4 were added to a ligation reaction solution (66 mM Tris-HCI).
, p) 17.6, 6.6 mM MgCl
, 0,5mM ATP, 10mM DTT), 45
80μ containing T4 DNAIJ gauze from QUnit7
The cells were incubated for 30 minutes at 16° C. in a solution of 1 ml. 6
After stopping the reaction at 5° C. for 10 minutes, agarose gel electrophoresis was performed to recover the desired 1-2 bp DNA fragment.
(1−3)pUc118NTの構築
分泌型発現ベクターpIN m−ompAl [ジ
ェンボ ジャーナル、第3巻、第2437〜2442頁
(1984)) lμgをBam)I I及び5alI
で分解し、アガロースゲル電気泳動にかけ、lppター
ミネータ−配列を含む0.95kbのBam旧Sal
I断片を回収した。この断片30ngをあらかじめBa
mHI及び5alIで分解して脱リン酸したプラスミド
ル旧18N〔フェブス レターズ(PH10
BS Letters) 、第223巻、第174〜1
80頁(1987)130ngとライゲーションした後
、大腸菌HBIO1を形質転換し、1ppターミネータ
−配列をもつプラスミドを得、p[Ic118NTと命
名した。(1-3) Construction of pUc118NT Secretory expression vector pIN m-ompAl [di
Embo Journal, Vol. 3, pp. 2437-2442 (1984)) lμg Bam) II and 5alI
and subjected to agarose gel electrophoresis to generate a 0.95 kb Bam old Sal containing the lpp terminator sequence.
The I fragment was recovered. 30 ng of this fragment was preliminarily
Plasmid old 18N degraded and dephosphorylated with mHI and 5alI [PH10 BS Letters, Vol. 223, No. 174-1
After ligation with 130 ng of p. 80 (1987), E. coli HBIO1 was transformed to obtain a plasmid with a 1 pp terminator sequence, which was named p[Ic118NT.
(1−4) ヒトEGFをコートする合成りNAのp
Uc118NTへのクローニング
(1−2)で得た172bflのDNA断片1.0μg
を前述の方法に従いリン酸化した。一方(1−3)で得
たpUc118NT I J−L gをNcoI及び
EcoRIで分解し、アガロースゲル電気泳動によりD
NA断片を回収した。得られたpUC118NT断片と
1?2bp断片とを前述の方法に従いライゲーションし
、大腸菌HB101を形質転換した。(1-4) Synthetic NA p coating human EGF
1.0μg of 172bfl DNA fragment obtained by cloning (1-2) into Uc118NT
was phosphorylated according to the method described above. On the other hand, pUc118NT I J-Lg obtained in (1-3) was digested with NcoI and EcoRI, and D
NA fragments were collected. The obtained pUC118NT fragment and 1-2 bp fragment were ligated according to the method described above, and E. coli HB101 was transformed.
(1−5)形質転換体中のプラスミドの分析(1−4)
で得られた形質転換体 14クローンについてプラスミ
ドの分析を行った。すなわち、ラピッド法でプラスミド
を調製し、NcoI及びEcoRIで分解し、アガロー
スゲル8
電気泳動にかけ、予想されるNcoI−Ec。(1-5) Analysis of plasmids in transformants (1-4)
Plasmid analysis was performed on 14 clones of the transformants obtained. That is, a plasmid was prepared by the rapid method, digested with NcoI and EcoRI, and subjected to agarose gel 8 electrophoresis to obtain the expected NcoI-Ec.
RI断片172b11の生成を調べた。しかし、目的の
バンドが生成するクローンはなかったため、うち2クロ
ーンについてジデオキシ法により、塩基配列の解析を行
ったところ、NCO■サイトの上流6塩基目から80塩
基対、すなわち、5 ′ −八ACAGACCATGG
CTAATAGCGATTCTGAGTGCCCACT
GTCTCACGACGGTTACTGTCTGCAT
GATGGCGTATGCATGTA[ニー3’の配列
の欠失が認められた。このプラスミドをp[JC118
NT−E G F (C)と命名した。The production of RI fragment 172b11 was investigated. However, since none of the clones produced the desired band, the base sequences of two of the clones were analyzed by the dideoxy method, and it was found that 80 base pairs from the 6th base upstream of the NCO site, that is, 5'-8ACAGACCATGG
CTAATAGCGATTCTGAGTGCCCACT
GTCTCACGACGGTTACTGTCTGCAT
GATGGCGTATGCATGTA [knee 3' sequence deletion was observed. This plasmid was p[JC118
It was named NT-EGF (C).
(1−6)欠失部分のDNA断片の調製EGF遺伝子の
N末の欠失部分を再構築するため、センス鎖としてEG
F S 56mer。(1-6) Preparation of DNA fragment of the deleted part In order to reconstruct the deleted part of the N-terminus of the EGF gene, we
FS 56mer.
アンチセンス鎖としてEGF A 58marの2
本のDNA (配列は第2図参照)を(1−2)と同様
にして合成し、アニーリング操作を行った後、フレノウ
酵素を用いて二重鎖DNAとした。すなわち、EGF−
32,08g、EGFA2.0μgを95μlのフレノ
ウ酵素用バッファ [7mM ) リ
ス HCI 、 pH7,5、20mM NaC
19
7mM MgCl2.0.1mMEDTA:Iに溶解し
、70℃に20分間保持した後、徐々に室温に戻し、各
20μMのdATP、dGTP、dCTP。EGF A 58mar 2 as antisense strand
Book DNA (see Figure 2 for the sequence) was synthesized in the same manner as in (1-2), annealed, and then converted into double-stranded DNA using Frenow enzyme. That is, EGF-
32.08g, EGFA 2.0μg and 95μl of Frenau enzyme buffer [7mM] Lis HCI, pH 7.5, 20mM NaC
19 7mM MgCl2. Dissolved in 0.1mM EDTA:I, kept at 70°C for 20 minutes, and then gradually returned to room temperature. 20μM each of dATP, dGTP, and dCTP.
TTPと1ユニツトのフレノウ酵素を加え、室温で20
分インキュベートした。65℃、10分の処理で反応を
停止した後、NcoI及びHinclIIIで分解し、
アガロースゲル電気泳動によりN c o I −1(
indlll断片78 bp 3.08gを得た。Add TTP and 1 unit of Freneau enzyme and incubate for 20 minutes at room temperature.
Incubated for minutes. After stopping the reaction at 65°C for 10 minutes, decomposition with NcoI and HinclIII,
Nco I-1 (
3.08 g of indlll fragment 78 bp was obtained.
(1−7) pUC118NT−E G F (C)の
EGFC末断片のpTF7520へのクロー
ニング
(1−5)で得たpUC118NT−E G F (C
)をHindlII及び5alIで分解し、アガロース
ゲル電気泳動により、HindIII −5ail断片
1. Okbを得た。(1-7) Cloning of the EGFC-terminal fragment of pUC118NT-E GF (C) into pTF7520 (1-5) pUC118NT-E GF (C)
) was digested with HindIII and 5alI, and the HindIII-5ail fragment 1. Got Okb.
一方、pTF7520をl1indIII及び5all
で分解し、アガロケースゲル電気泳動によりHindI
IISail断片4.0kbを回収した。この断片と、
先のHindI[l−3ail 1.Ok b断片をラ
イゲーションし、大腸菌1(BIOIを形質転換した。On the other hand, pTF7520 was added to l1indIII and 5all
and HindI by agarocase gel electrophoresis.
An IISail fragment of 4.0 kb was recovered. This fragment and
Previous HindI[l-3ail 1. The Ok b fragment was ligated and transformed into E. coli 1 (BIOI).
得られた形質転換体についてプラスミドの分析を行い、
目的の0
プラスミドをpTF 7520−EGF (C)と命名
した。Plasmid analysis was performed on the obtained transformants,
The desired 0 plasmid was named pTF7520-EGF (C).
(1−8)発現プラスミドの構築と確認(1−7>で得
られたpTF7520−EGF (C)をNcoI及び
HindI[Iで分解し、アガロースゲル電気泳動によ
り、5.0kbの断片を回収した。これと、(1−6)
で得たNcoIHindII[断片をライゲーションし
、大腸菌HBIOIを形質転換した。得られた形質転換
体についてプラスミドを調製し、NC0I及びEcoR
Iで分解し、アガロースゲル電気泳動により172bp
の断片が生成することを確認し、更にジデオキシ法によ
り、塩基配列の解析を行い、目的の配列を含むことを確
認した。この組換え体プラスミドをpcE102と命名
した。このpCE102によって発現されるポリペプチ
ドの細胞接着ドメインとEGFの間にはMet Al
aが付加されている。このMet−Alaに対応する配
列(ATGGCT)を以下に述べるごとく、部位特異的
変異の手法により除去した。オリゴヌク2ル
オチドd [AATCGCTATTGGATGGTTT
G)を合成し、サイト−ダイレクチイド ミュークジェ
ネシス システム ミュータン−Kを用いて行った。そ
の結果、細胞接着ドメイン(前記式■)とEGF (前
記式■)が直接結合したポリペプチドを発現するプラス
ミドを得、pcE103と命名した。(1-8) Construction and confirmation of expression plasmid (pTF7520-EGF (C) obtained in 1-7> was digested with NcoI and HindI[I, and a 5.0 kb fragment was recovered by agarose gel electrophoresis. .This and (1-6)
The NcoIHindII fragment obtained was ligated and transformed into E. coli HBIOI. A plasmid was prepared for the obtained transformant, and NCOI and EcoR
172bp by agarose gel electrophoresis.
It was confirmed that a fragment was generated, and the base sequence was further analyzed by the dideoxy method, and it was confirmed that the target sequence was contained. This recombinant plasmid was named pcE102. There is MetAl between the cell adhesion domain of the polypeptide expressed by pCE102 and EGF.
a is added. The sequence (ATGGCT) corresponding to this Met-Ala was removed by site-directed mutagenesis as described below. Oligonuc 2 luotide d [AATCGCTATTGGATGGTTT
G) was synthesized using the cytodirected mukgenesis system Mutan-K. As a result, a plasmid expressing a polypeptide in which the cell adhesion domain (formula 2 above) and EGF (formula 2 above) were directly bound was obtained and named pcE103.
pCE 102を保持する大腸菌118101をEsc
herichia coli HB 101/pCE
102と表示し、工業技術院微生物工業技術研究所に寄
託した〔微工研菌寄第11226号(FERMP−11
226))。Esc. coli 118101 harboring pCE 102
herichia coli HB 101/pCE
102 and has been deposited with the Institute of Microbial Technology, Agency of Industrial Science and Technology [FERMP-11
226)).
実施例2 組換え体からのポリペプチドの精製(1−8
)で得た口5cherichia coli HB
101/pCE 102を50gg/m1のアンピシリ
ンを添加した5mlのし一ブロスを含む試験管で37℃
、−夜振とう培養した。これを500艷の同培地を含む
2j2の三角フラスコ4本に接種し、100 rpmで
培養を続けた。660nmの吸光度が0.3の時点でI
PTG(イソプロピル2
β−D−ヂオガラクトシド)を2mMになるよう添加し
、16時間後に集菌した。菌体の一部を用いてイムノブ
ロッティングを行った。すなわち、全菌体タンパク質を
5DS−PAGE (ポリアクリルアミドゲル電気泳動
)で分離し、泳動パターンをニトロセルロースメンプラ
ンに転写した後、FNの細胞接着ドメインを特異的に認
識するモノクローナル抗体[:FN12−8、全酒造〕
、また一方ではヒ)EGFを特異的に認識するモノクロ
ーナル抗体〔湧水製薬〕を作用させ、次いでパーオキシ
ダーゼ標識第2抗体を作用させた。結合した第2抗体の
パーオキシダーゼ活性により4−クロロ−1−ナフトー
ルと過酸化水素の存在下で発色させ、いずれのモノクロ
ーナル抗体の場合でも、37kD付近に目的のペプチド
が生産されていることを確認した。Example 2 Purification of polypeptide from recombinant (1-8
) Obtained from Cherichia coli HB
101/pCE 102 at 37°C in a test tube containing 5 ml of Shiichi broth supplemented with 50 gg/ml of ampicillin.
, - overnight shaking culture. This was inoculated into four 2J2 Erlenmeyer flasks containing 500 cells of the same medium, and culture was continued at 100 rpm. When the absorbance at 660 nm is 0.3, I
PTG (isopropyl 2 β-D-diogalactoside) was added to a concentration of 2 mM, and bacteria were collected 16 hours later. Immunoblotting was performed using a portion of the bacterial cells. That is, after separating all bacterial cell proteins by 5DS-PAGE (polyacrylamide gel electrophoresis) and transferring the migration pattern to nitrocellulose membrane, a monoclonal antibody that specifically recognizes the cell adhesion domain of FN [:FN12- 8. Zenshuzo]
On the other hand, a monoclonal antibody [Yusui Pharmaceutical Co., Ltd.] that specifically recognizes human EGF was applied, and then a peroxidase-labeled second antibody was applied. Color was developed in the presence of 4-chloro-1-naphthol and hydrogen peroxide due to the peroxidase activity of the bound second antibody, and it was confirmed that the target peptide around 37 kD was produced with either monoclonal antibody. did.
次に、全菌体ペレットを緩衝液[50mM)UスHCI
、pHB、 0.25%ショ糖、1mM EDTA:
]50−に懸濁し、2 mg / 艷!Iゾチーム溶液
を2誦添加した。0℃、30分放置後、超音波処理3
することにより菌体を破砕した。この菌体破砕液に、I
M MgCl2を150μβ、及び60,000ユニ
ツト/艷デオキシリボヌクレアーゼI (DNase
I)を125μftそれぞれ添加し、37℃、30分イ
ンキュベートした。次いで、0.2M NaC1,1
%デオキシコール酸、1%ノニデッ トP−40を含む
20mM) リス HCI、pH17,5緩衝液10
mffを添加し、12.00 Orpmで10分間遠心
分離し、上澄みを捨てた。沈殿を緩衝液 (50mM)
リス HCI、pH8,o、 10mMEDTA、
1 0 0 mM NaC1,0,5% ト
リ ト ンX −100)40−に懸濁し、14.0
00.rpmで10分間遠心分離し上澄みを捨てた。こ
の沈殿を次いで20%エチレングリコール水溶液40m
1に懸濁し、14、 OOOrpmで10分間遠心分離
した。得られた沈殿を更に2%ノニデッ)P−40水溶
液40艷に懸濁し、14.00 Orpmで10分間遠
心分離し上澄みを捨てることにより精製された封入体4
50mg(湿重量)のペレットを得た。Next, the whole bacterial pellet was diluted with buffer [50mM] US HCI.
, pHB, 0.25% sucrose, 1mM EDTA:
]50-, suspended in 2 mg/艷! Isozyme solution was added twice. After being left at 0°C for 30 minutes, the bacterial cells were disrupted by ultrasonication 3. In this bacterial cell disruption solution, I
150μβ of MgCl2 and 60,000 units/deoxyribonuclease I (DNase
125 μft of each of I) was added and incubated at 37° C. for 30 minutes. Then 0.2M NaCl,1
% deoxycholic acid, 20mM containing 1% Nonidet P-40) Squirrel HCI, pH 17,5 buffer 10
mff was added, centrifuged at 12.00 Orpm for 10 minutes, and the supernatant was discarded. Precipitate with buffer solution (50mM)
Squirrel HCI, pH 8, o, 10mMEDTA,
100 mM NaCl 1.0.5%
Suspended in Liton X-100) 40-, 14.0
00. Centrifugation was performed at rpm for 10 minutes and the supernatant was discarded. This precipitate was then washed with 40ml of 20% ethylene glycol aqueous solution.
1 and centrifuged at 14,000 rpm for 10 minutes. The resulting precipitate was further suspended in 40 2% Nonidet P-40 aqueous solution, centrifuged at 14.00 Orpm for 10 minutes, and the supernatant was discarded to obtain purified inclusion bodies 4.
A pellet of 50 mg (wet weight) was obtained.
この封入体を20mM)リスHCL pi(8,0,2
504
mMDTT、6M尿素液25m1に溶解した。This inclusion body was mixed with 20mM) squirrel HCL pi (8,0,2
504 mM DTT was dissolved in 25 ml of 6M urea solution.
これを、20mM)リス HCI pH8,0,10m
MDTTで平衡化したDEAE−)ヨパール650S(
東ソー)15−のカラムに通した。同一バッファーで非
吸着画分を除いた後、020mM)リスIIcI、pH
8,0,10n+MDTT、 100mM NaC1、
次いで020mM)リスHCI、pH8,0,10mM
DTT、 200mM NaC1更に020mM)リス
HCI、pH8,0,10mMDTT、 300 m
M NaC1で段階的に溶出し、分画した。溶出液につ
いてSDSポリアクリルアミド電気泳動を行ったところ
、■の溶出画分において、電気泳動的にほぼ単一な目的
ポリペプチドを確δ忍した。Add this to 20mM) Squirrel HCI pH8,0,10m
DEAE-) Yopal 650S (DEAE-) equilibrated with MDTT
Tosoh) 15- column. After removing the non-adsorbed fraction with the same buffer, 020 mM) Lis IIcI, pH
8,0,10n+MDTT, 100mM NaCl,
then 020mM) Lis HCI, pH 8,0,10mM
DTT, 200mM NaCl plus 020mM) Lis HCI, pH 8,0,10mM DTT, 300 m
Stepwise elution and fractionation were performed with M NaCl. When the eluate was subjected to SDS polyacrylamide electrophoresis, the target polypeptide, which was electrophoretically homogeneous, was confirmed to be present in the eluted fraction (■).
この両分を、1mM還元型グルタチオン、0.1mM酸
化型グルタチオンを含む20mMトリス)ICI、pH
7,5緩衝液中で4℃、二昼夜透析することにより、ポ
リペプチドのりフォールディングを行った。この透析内
液をPBS (!Jン酸緩衝化生理食塩水)に透析し、
目的ポリペプチド12mgを得た。Both parts were mixed with 20mM Tris) ICI containing 1mM reduced glutathione and 0.1mM oxidized glutathione, pH
Polypeptide glue folding was performed by dialysis in 7,5 buffer at 4°C for two days and nights. This dialyzed fluid was dialyzed against PBS (!J acid buffered saline),
12 mg of the target polypeptide was obtained.
5
本ポリペプチドのN末端からのアミノ酸配列を、アプラ
イドバイオシステムズ社のペプチドシーケンサ−477
A/12OAを用いて調べたところ、Pro −Thr
−Asp −Leu −Arg −Phe −Thr
の配列が認められ、目的ポリペプチドの配列と一致した
。以下、本ポリペプチドをC−EGFと称する。5 The amino acid sequence from the N-terminus of this polypeptide was analyzed using Applied Biosystems' Peptide Sequencer-477.
When investigated using A/12OA, Pro-Thr
-Asp -Leu -Arg -Phe -Thr
The sequence was found to match that of the target polypeptide. Hereinafter, this polypeptide will be referred to as C-EGF.
実施例3 生物活性の測定
前記実施例2で得られたポリペプチドC−EGFを用い
て、細胞接着活性及び細胞増殖促進活性を測定した。Example 3 Measurement of biological activity Using the polypeptide C-EGF obtained in Example 2, cell adhesion activity and cell growth promoting activity were measured.
(3−1)細胞接着活性の測定
細胞接着活性は、ルオスラティらの方法〔メンツズ イ
ン エンザイモロジー、第82巻、第803〜831頁
(1981) )に準じて測定した。試料を蒸留水、P
BS (!Jン酸緩衝化生理食塩水)等に溶かし、96
穴マイクロプレートに注入した。4℃、2時間インキュ
ベートして、試料をプレート上に吸着させた(50μβ
/ウエル)。3%BSA (牛血清アルブミン)6
を含むPBS溶液を100μm/ウェル加え、37℃、
1時間インキュベートしてプレートをブロックした。P
BSでプレートを洗浄後、あらかじめダルベツコ(Du
lbecco・S)イーグル最小栄養培地(口MBM)
に5X105細胞/ml!となるように懸濁させたベビ
ーハムスター腎細胞(BHK−21)を100μβ/ウ
ェル分注し、37℃、1時間インキュベートした。なお
使用したBHK−21細胞は、凍結保存した株を総代培
養後、トリプシン処理(37℃、5分)したものを用い
た。PBSでプレートを洗浄後、3%ホルマリン溶液で
細胞をプレート上に固定した。(3-1) Measurement of cell adhesion activity Cell adhesion activity was measured according to the method of Luoslati et al. [Men's in Enzymology, Vol. 82, pp. 803-831 (1981)]. Distilled water, P
Dissolve in BS (!J acid buffered saline) etc.
injected into a well microplate. The sample was adsorbed onto the plate by incubation at 4°C for 2 hours (50 μβ
/well). Add 100 μm/well of PBS solution containing 3% BSA (bovine serum albumin) and incubate at 37°C.
Plates were blocked by incubating for 1 hour. P
After washing the plate with BS, use Dulbecco (Dulbecco) in advance.
lbecco・S) Eagle minimal nutrient medium (MBM)
5X105 cells/ml! Baby hamster kidney cells (BHK-21) were suspended at 100 μβ/well and incubated at 37° C. for 1 hour. The BHK-21 cells used were cryopreserved strains that were cultured and then treated with trypsin (37°C, 5 minutes). After washing the plate with PBS, cells were fixed on the plate with a 3% formalin solution.
顕微鏡下でBHK−21細胞の伸展を観察し、細胞伸展
性より細胞接着活性を測定した。The spread of BHK-21 cells was observed under a microscope, and cell adhesion activity was measured from cell spreadability.
C−EGF、及びヒトEGF (湧水製薬)の結果を第
1表に示す。The results for C-EGF and human EGF (Yusui Seiyaku) are shown in Table 1.
第 表 試料 細 胞 (0,05μM) 接着活性 C−EGF 十+十 EGF 数値は試料をプレートに吸着させた際の濃度を示す。No. table Sample Cell (0.05 μM) Adhesion activity C-EGF 10+10 EGF The numerical value indicates the concentration when the sample is adsorbed onto the plate.
(3−2)細胞増殖促進活性(DNA合成促進活性)の
測定
あらかじめ継代培養したNRK−49F細胞を、10%
の牛胎児血清を含む、ダルベツコイーグル最小栄養培地
(10%FC3−DMEM)により、5X10’細胞/
mlに希釈し、200μβずつ96穴マイクロプレート
に分注した。(3-2) Measurement of cell proliferation promoting activity (DNA synthesis promoting activity) NRK-49F cells that had been subcultured in advance were
Dulbecco-Eagle Minimal Nutrient Medium (10% FC3-DMEM) containing fetal bovine serum
The solution was diluted to 100 ml and dispensed in 200 μβ portions into a 96-well microplate.
5%CO2存在下、37℃で3日間培養し、PBSによ
り段階的に希釈した試料を40μβずつ各ウェルに加え
た。37℃にて18時間培養し8
た後、5μCi/誦の3H−チミジンを20μβずつ各
ウェルに添加し、更に、37℃にて、6時間培養した。The cells were cultured at 37° C. for 3 days in the presence of 5% CO2, and 40 μβ of samples diluted serially with PBS were added to each well. After culturing at 37°C for 18 hours, 20 μβ of 3H-thymidine (5 μCi/ml) was added to each well, and the cells were further cultured at 37°C for 6 hours.
培地を吸い取り、PBSで2回洗浄した後、0.1%ト
リプシン溶液100μlを各ウェルに加え、37℃で2
時間インキュベートし、細胞がはく離していることを顕
微鏡下で確認した。セルハーベスタ−(フローラボラト
リーズ社製)にグラスフィルターをセットし、ウェル中
の細胞を吸引し、細胞を吸着させたフィルターを乾燥さ
せた後、液体シンチレーションカウンターにより3日−
チミジンの取込みを測定した。その結果、本ポリペプチ
ドにおいて、対照としたヒトEGFと同等の3■−チミ
ジンの取込みが認められた。一方、負の対照とした特開
平1−206998号公報記載の279アミノ酸残基ポ
リペプチド(C−279)においては、取込みは認めら
れなかった(第2表参照)。After aspirating the medium and washing twice with PBS, 100 μl of 0.1% trypsin solution was added to each well and incubated at 37°C for 2
After incubation for an hour, it was confirmed under a microscope that the cells had detached. A glass filter was set in a cell harvester (manufactured by Flow Laboratories), and the cells in the well were aspirated. After drying the filter with the cells adsorbed, it was stored in a liquid scintillation counter for 3 days.
Thymidine incorporation was measured. As a result, the incorporation of 3■-thymidine in this polypeptide was found to be equivalent to that in human EGF used as a control. On the other hand, no incorporation was observed in the 279 amino acid residue polypeptide (C-279) described in JP-A-1-206998, which was used as a negative control (see Table 2).
9
第
表
試料濃& C−BGF EIGF C−27
9(μM) 3H−チミジンの取込み(X 103
103dp、5 4.7 5.0 0
.62.3 5J 4.8 0.4
1.1 2.7 2.5 0.20.
56 2.5 2.1 0.80.2
B 1.9 1.8 0.5〔発明
の効果〕
以上述べてきたごとく、本発明により、細胞接着活性と
細胞増殖促進活性の両活性を合せ持つ機能性ポリペプチ
ドとその製造方法が提供された。9 Table Sample concentration & C-BGF EIGF C-27
9 (μM) 3H-thymidine incorporation (X 103
103dp, 5 4.7 5.0 0
.. 62.3 5J 4.8 0.4
1.1 2.7 2.5 0.20.
56 2.5 2.1 0.80.2
B 1.9 1.8 0.5 [Effects of the Invention] As described above, the present invention provides a functional polypeptide having both cell adhesion activity and cell proliferation promoting activity, and a method for producing the same. Ta.
上記ポリペプチドは、EGFと細胞との親和性を高める
ことができ、創傷治癒等などの用途において非常に有用
である。The above polypeptide can increase the affinity between EGF and cells, and is very useful in applications such as wound healing.
0
第1図はEGF遺伝子の5′側80bpが欠失したプラ
スミドp[I[:118NT−E G F (C)を構
築するための工程図、第2図は本発明のC27□−XE
GFをコードするプラスミドpcE102を構築するだ
めの工程図である。0 Figure 1 is a process diagram for constructing the plasmid p[I[:118NT-E G
FIG. 2 is a process diagram for constructing plasmid pcE102 encoding GF.
Claims (1)
式中、C_2_7_7はヒトフィブロネクチンの細胞接
着ドメインのPro^1^2^3^9^−Ser^1^
5^1^5^に相当する277アミノ酸ポリペプチド残
基を示し、下記式II: 【遺伝子配列があります。】 ・・・〔II〕 で表される配列を有し、Xはメチオニル−アラニン残基
(Met−Ala)を示し、nは1又は零の数を示し、
EGFはヒト上皮成長因子のアミノ酸残基を示し、下記
式III: 【遺伝子配列があります。】 ・・・・〔III〕 で表される配列を有する〕で表されることを特徴とする
機能性ポリペプチド。[Claims] 1. The following general formula I: C_2_7_7-(X)n-EGF...[I][
In the formula, C_2_7_7 is Pro^1^2^3^9^-Ser^1^ of the cell adhesion domain of human fibronectin.
It shows the 277 amino acid polypeptide residues corresponding to 5^1^5^, and has the following formula II: [There is a gene sequence. ] ... [II] It has a sequence represented by
EGF indicates the amino acid residue of human epidermal growth factor, and has the following formula III: [Gene sequence is available. ] ...[III] A functional polypeptide characterized by having a sequence represented by:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024469A JP2866134B2 (en) | 1990-02-05 | 1990-02-05 | Functional polypeptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024469A JP2866134B2 (en) | 1990-02-05 | 1990-02-05 | Functional polypeptide |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03232898A true JPH03232898A (en) | 1991-10-16 |
JP2866134B2 JP2866134B2 (en) | 1999-03-08 |
Family
ID=12139027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024469A Expired - Fee Related JP2866134B2 (en) | 1990-02-05 | 1990-02-05 | Functional polypeptide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2866134B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5302701A (en) * | 1991-10-14 | 1994-04-12 | Takara Shuzo Co., Ltd. | Polypeptide having human fibronectin-like cell adhesive activity |
WO2003004066A1 (en) * | 2001-07-05 | 2003-01-16 | Takara Bio Inc. | Gene therapeutics |
WO2011063477A1 (en) * | 2009-11-30 | 2011-06-03 | Queensland University Of Technology | Fibronectin: growth factor chimeras |
JP2011120595A (en) * | 2003-02-05 | 2011-06-23 | Queensland Univ Of Technology | Growth factor complex and modulation of cell migration and growth |
US9090706B2 (en) | 2003-02-05 | 2015-07-28 | Queensland University Of Technology | Fibronectin: growth factor chimeras |
-
1990
- 1990-02-05 JP JP2024469A patent/JP2866134B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5302701A (en) * | 1991-10-14 | 1994-04-12 | Takara Shuzo Co., Ltd. | Polypeptide having human fibronectin-like cell adhesive activity |
WO2003004066A1 (en) * | 2001-07-05 | 2003-01-16 | Takara Bio Inc. | Gene therapeutics |
JP2011120595A (en) * | 2003-02-05 | 2011-06-23 | Queensland Univ Of Technology | Growth factor complex and modulation of cell migration and growth |
US9090706B2 (en) | 2003-02-05 | 2015-07-28 | Queensland University Of Technology | Fibronectin: growth factor chimeras |
WO2011063477A1 (en) * | 2009-11-30 | 2011-06-03 | Queensland University Of Technology | Fibronectin: growth factor chimeras |
CN102725308A (en) * | 2009-11-30 | 2012-10-10 | 昆士兰技术大学 | Fibronectin: growth factor chimeras |
Also Published As
Publication number | Publication date |
---|---|
JP2866134B2 (en) | 1999-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69827507T2 (en) | TRIMERIZING MODULE | |
JP3045398B2 (en) | Proteins, DNAs and their uses | |
US5198423A (en) | Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin | |
US5512460A (en) | Glia activating factor and its production | |
US8324344B2 (en) | Membrane transduction peptides and methods of delivering material to a target cell | |
TR201802360T4 (en) | Specific prongf mutants and their use in beta-ngf production. | |
AU758576B2 (en) | Chemokines with amino-terminal modifications | |
JP2829405B2 (en) | Functional polypeptide | |
JPH05503512A (en) | [ALA IL-8] as a leukocyte adhesion inhibitor ↓7↓7 | |
JPH07507270A (en) | Therapeutic domain of von Willebrand factor | |
JPH02231499A (en) | Novel protein h, having immunoglobulin g binding activity, gene coding same protein and production of same protein | |
JPH03232898A (en) | Functional polypeptide | |
PT93178B (en) | ANTICANCEROSO PROTEIN AGENT | |
US20110230421A1 (en) | Fusion proteins of apoptin-protein transduction domain of carboxyl-terminus of ec-sod | |
WO1992005276A1 (en) | A method for over-expression and rapid purification of biosynthetic proteins | |
JP2561149B2 (en) | Functional polypeptide | |
KR101651330B1 (en) | Methods of TAT-A20 fusion protein with good cell penetration and use thereof | |
JP2561122B2 (en) | Functional polypeptide | |
JPH08503614A (en) | Purification of a fusion protein containing GM-CSF and IL-3 | |
JPH1029952A (en) | Composition for controlling human immunodeficiency virus infection and controlling thereby | |
JP2829397B2 (en) | Fibrin binding active polypeptide | |
JP2864152B2 (en) | Functional polypeptide | |
JPH0276596A (en) | Human granulocyte microphage colony stimulation factor derivative and expression vector for producing the same | |
Brandt-Rauf et al. | The structure of the carboxyl terminus of the p21 protein. Structural relationship to the nucleotide-binding/transforming regions of the protein | |
JP2854445B2 (en) | Functional polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071218 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081218 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |